bioRxiv Science⌕ Search

bioRxiv · 10.64898/2026.02.12.705547

Generative AI Guided Design of High-Affinity T cell Receptors

Abstract

Developing T cell receptors (TCRs) with sufficiently high affinity for tumor antigens (TAs) remains a fundamental challenge in TCR-T immunotherapy. Experimental methods such as affinity maturation and high-throughput screening have enabled the identification of TCRs with enhanced activity. However, their efficiency is often constrained by limited throughput, insufficient coverage, and the generally lower affinities of naturally occurring TCRs toward TAs. To address these challenges, we present TCRPPO2, an integrated AI-driven, in silico affinity maturation framework for peptide-specific TCR optimization. Using reinforcement learning, TCRPPO2 learns mutation policies that iteratively enhance the TCR binding affinity to the target peptide, derived from predictive models trained on carefully curated interaction data. The model is further augmented by a generative AI critic model that discourages implausible designs to ensure the biophysical validity. The designs are further screened by robust post-screening methods that leverage diverse functional annotations and physical prior knowledge. We applied TCRPPO2 to the clinically relevant MART-1 antigen and experimentally validated the designed candidates in Jurkat cell-based functional assays. Among the five engineered TCRs, all of which demonstrated positive cellular responses, three showed significantly increased activities relative to their templates and one showed substantial enhancement. These functional gains were consistent with more favorable interaction energy from structural and physical modeling. Together, our results support a generalizable paradigm for TCR engineering, in which learned mutation policies can efficiently navigate the peptide-specific binding landscape of TCRs and propose biologically enhanced candidates without explicit structural supervision, offering a practical route for early-stage computational TCR optimization for challenging tumor antigens.

Explore related subjects

Keep this discovery

Explore connections, maps & timelines

BibTeXRIS

Min, M. R., Li, T., Onoguchi, K., Mori, D., Demachi-Okamura, A., Warrell, J., Machart, P., Moesch, A., Meiser, A., Pait, I. G., Muraoka, D., Matsushita, H., Paiardi, G., Ferraz, M., Bendjama, K.. 2026-02-12. Generative AI Guided Design of High-Affinity T cell Receptors. https://doi.org/10.64898/2026.02.12.705547

Cite the original work for its findings. Save a collection to share your selection of sources.

KEEP EXPLORING

Related preprints

ACE-engineered human iPSC-derived neutrophils enhance host defense against multidrug-resistant bacterial infections

Severe neutropenia predisposes patients to life-threatening infections, while donor-dependent granulocyte transfusions are limited by availability and variable cell quality. Here, we engineered human induced pluripotent stem cells (iPSCs) to constitutively or inducibly express angiotensin-converting enzyme (ACE) and differentiated them into functional ACE-engineered neutrophils (ACE-iNeu). ACE expression enhanced granulocytic maturation, reactive oxygen species generation, inflammatory cytokine production, and antimicrobial signaling. ACE-iNeu exhibited enhanced bactericidal activity against methicillin-resistant Staphylococcus aureus and multidrug-resistant Pseudomonas aeruginosa. Following adoptive transfer into neutropenic mice, ACE-iNeu significantly reduced circulating and tissue bacterial burdens. Integrated metabolomic and transcriptomic analyses revealed ACE-associated alterations in adenine nucleotide abundance and developmental and inflammatory pathways. Together, these findings establish ACE engineering as a strategy to enhance the production and antimicrobial function of human iPSC-derived neutrophils and support further preclinical development of engineered granulocyte therapies for severe drug-resistant infections.

immunology↗

Tetravalent dengue mRNA vaccination orchestrates balanced four-serotype immunity with durable memory and protection in mice.

An effective dengue vaccine must establish durable immunity across four dengue virus (DENV) serotypes, evade antibody-dependent enhancement (ADE), and overcome immune imprinting from prior exposure. Here, we developed TetprM-E mRNA-LNP, a tetravalent vaccine comprising LNP-formulated nucleoside-modified mRNAs encoding DENV1-4 precursor membrane-envelope (prM-E) antigens, and evaluated its immunogenicity, durability, protection and breath across serotype-specific immune backgrounds. Three immunization strategies elicited neutralizing titers greater than 1:1500 against each serotype. Passive transfer of immune sera conferred 100% survival and reduced viremia after lethal DENV2 challenge in immunocompromised mice. Vaccination induced DENV envelope (env)-specific CD8+T cells and CD4-dependent germinal-center responses. DENV env-binding antibodies persisted for 34 weeks alongside DENV env-specific memory B cells. Vaccine-elicited sera showed no measurable in vitro ADE. Although monovalent priming initially biased antibody responses, TetprM-E mRNA-LNP vaccination broadened neutralization across DENV1-4 regardless of priming serotype. Together, TetprM-E mRNA-LNP elicits broad, durable, and protective immunity despite serologic constraints from pre-existing immunity.

immunology↗

The antagonism of sex chromosomes and sex hormones dictates outcomes in Th17 cell-mediated central nervous system autoimmunity.

Biological sex traits are shaped by the combined effects of both sex hormones and chromosomes. How these factors interact in sex-related autoimmune diseases, such as multiple sclerosis (MS), has been a subject of intense recent interest. Here, using the Four Core Genotype (FCG) mouse model, in which these two variables can be disentangled, we describe an antagonism between sex hormones and chromosomes that potently influences outcomes in T helper 17 (Th17)-driven progressive central nervous system (CNS) autoimmunity. Male gonadal hormones dampen disease severity, irrespective of sex chromosome complement, by promoting a Wnt/{beta}-catenin signaling program associated with a homeostatic, non-pathogenic Th17 phenotype. By contrast, XY chromosomal complement exacerbates Th17 pathogenicity in a recipient sex-dependent manner; we identify the X-linked molecule SUV39H1 as an inhibitor of inflammatory Th17 cell function. Unexpectedly, we found that hormonally and chromosomally female FCG Th17 cells induced far more severe disease than WT female counterparts despite being genetically identical, pointing to a parental imprinting effect in dictating Th17 cell pathogenicity. These latter investigations uncovered Runx2, a transcription factor previously linked to developmental programs, as a novel negative regulator of the pathogenicity of Th17 cells. Together, our findings establish biological sex as a multilayered regulator of Th17 pathogenicity, revealing distinct and sometimes opposing contributions of hormones, chromosomes, and parental inheritance.

immunology↗